Want to see KR:000520 full AI Analyst Report?
Samil Pharmaceutical Co., Ltd. (000520) Income Statement
Samil Pharmaceutical Co., Ltd. Income Statement
Last quarter (Q2 2026), Samil Pharmaceutical Co., Ltd.'s total revenue was ₩50.60B, a decrease of 5.92% from the same quarter last year. In Q2, Samil Pharmaceutical Co., Ltd.'s net income was ₩-7.69B. See Samil Pharmaceutical Co., Ltd.’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| ₩ 210.37B | ₩ 219.70B | ₩ 196.35B | ₩ 179.68B | ₩ 134.25B | |
| ₩ 67.44B | ₩ 80.91B | ₩ 72.21B | ₩ 67.49B | ₩ 48.99B | |
| ₩ 91.38B | ₩ 80.80B | ₩ 65.75B | ₩ 63.47B | ₩ 48.59B | |
| Depreciation and Amortization | ₩ 13.21B | ₩ 7.26B | ₩ 5.37B | ₩ 4.99B | ₩ 4.71B |
| ₩ -10.72B | ₩ 8.71B | ₩ 10.34B | ₩ 10.31B | ₩ 6.15B | |
| ₩ -23.94B | ₩ 113.04M | ₩ 6.47B | ₩ 4.02B | ₩ 399.74M | |
| ₩ -13.22B | ₩ -3.73B | ₩ -5.05B | ₩ -2.96B | ₩ -5.16B | |
| ₩ -37.16B | ₩ -3.61B | ₩ 1.42B | ₩ 1.06B | ₩ -4.76B | |
| ₩ -34.59B | ₩ -5.63B | ₩ 1.66B | ₩ -28.29M | ₩ -5.35B | |
| Per Share Metrics | |||||
| Basic EPS | ₩ -1627.95 | ₩ -313.00 | ₩ 116.16 | ₩ -2.03 | ₩ -386.63 |
| Diluted EPS | ₩ -1627.95 | ₩ -313.00 | ₩ 115.37 | ₩ -2.03 | ₩ -386.63 |
| Weighted Average Shares Outstanding | 21.25M | 17.98M | 14.32M | 13.91M | 13.83M |
| Weighted Average Shares Outstanding (Diluted) | 21.25M | 17.98M | 14.42M | 13.91M | 13.83M |
Currency in KRW
